BREAST CANCER AND THE ENVIRONMENT ON LONG ISLAND

乳腺癌与长岛的环境

• 批准号: 6667287
• 负责人: MARILIE D. GAMMON
• 金额: $ 40.8万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-08-08 至 2005-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6667287
• 关键词: breast neoplasms; cancer risk; carbopolycyclic compound; clinical research; cooperative study; dichlorodiphenyltrichloroethane; environment related neoplasm /cancer; female; gene mutation; halobiphenyl /halotriphenyl compound; human subject; longitudinal human study; neoplasm /cancer epidemiology; neoplasm /cancer genetics; oncogenes; p53 gene /protein; smoking; tobacco abuse; women's health

APPLICANT?S DESCRIPTION This continuation proposes to follow-up 1,508 case women newly diagnosed with breast cancer who are participants in an ongoing population-based, case-control study of breast cancer among women on Long Island. The primary aims of the ongoing parent case-control study are to determine whether risk of developing breast cancer is increased among women with higher levels of serum organochlorine compounds, including DDT and PCBs, or higher levels of polycyclic aromatic hydrocarbons, assessed by PAH-DNA levels in blood samples. The proposed continuation will follow-up the case women 3- and 5-years after diagnosis of the primary breast cancer to identity environmental factors that affect the risk of disease-free and overall survival, including: (1) serum levels of DDT and PCBs, and PAH-DNA adducts based on blood samples collected at the parent case-control interview; and (2) cigarette smoking, physical activity, hormone replacement therapy, changes in weight as an adult, alcohol diet, and other factors assessed by structured questionnaire during the parent case-control interview. An additional aim is to explore whether the survival risk associated with these potential environmental risk factors is modified by known prognostic indicators in the tumor, including p53 and HER-2/neu. During the 3- and 5-year follow-up periods, medical treatment and outcomes (recurrence, second primary) will be assessed by telephone interview with the subject and by checking with physicians and medical records. Mortality will be determined by cross-checking the National Death Index, and by contacting next of kin and physicians. For the parent study, blood samples were successfully obtained for 1,087 case women and assays of DDT/PCBs and PAH-DNA adducts will be completed as planned for 643 and 577 cases, respectively. Blood samples for the remaining 444 and 320 case women, respectively, with sufficient blood volume will be assayed for these environmental compound as part of the proposed study. Assays for HER2/neu overexpression in case tumor tissue, assessed by immunohistochemisty, will be conducted for the proposed follow-up; funding for the immunohistochemical assays of p53 expression has already been obtained. Standard statistical techniques for the analysis of cohort data will be used to determine the risk of disease-free survival and overall survival, at the 3- and 5-year follow-up periods, associated with higher levels of environmental factors, with adjustments made for breast cancer treatment, breast tumor characteristics, and other clinical predictors of survival. Potential subgroup effects, with cases partitioned on p53 and HER-2/neu expression, the relation between environmental factors on breast cancer survival will be explored, where possible.

申请人？的描述 这一延续建议对新诊断的1 508例妇女进行随访， 参与正在进行的基于人群的病例对照研究的乳腺癌患者 长岛女性乳腺癌研究主要目标 正在进行的母病例对照研究的目的是确定 乳腺癌的发病率在血清中 有机氯化合物，包括滴滴涕和多氯联苯，或更高水平的 多环芳烃，通过血液样本中的多环芳烃DNA水平进行评估。 拟议的继续将随访病例妇女3年和5年后， 诊断原发性乳腺癌，以确定环境因素， 影响无病生存期和总生存期的危险因素包括：（1）血清 根据采集的血液样本，滴滴涕和多氯联苯以及多环芳烃-DNA加合物的水平 在父母病例对照访谈;（2）吸烟，身体 活动，激素替代疗法，成年后体重变化，酒精 饮食和其他因素通过结构式问卷评估，在父母 病例对照访谈另一个目的是探索是否生存 与这些潜在环境风险因素相关的风险通过以下方式进行修改： 肿瘤中已知的预后指标，包括p53和HER-2/neu。期间 3年和5年随访期、药物治疗和结局 （复发，第二主要）将通过电话访谈进行评估， 受试者和检查医生和医疗记录。死亡率将 通过交叉检查国家死亡指数，并通过联系 近亲和医生在母研究中，采集血样， 成功地为1，087例妇女进行了滴滴涕/多氯联苯和多环芳烃DNA检测 将按计划分别完成643和577起案件的加合。 其余444例和320例妇女的血液样本，分别与 对于这些环境化合物，将测定足够血液体积， 这是拟议研究的一部分。肿瘤病例中HER 2/neu过表达的测定 组织，通过组织化学评估，将进行拟议的 随访; p53表达免疫组织化学检测的资金已经 已经获得。分析的标准统计技术 队列数据将用于确定无病生存的风险， 3年和5年随访期的总生存率，与 更高水平的环境因素，对乳房进行调整 癌症治疗、乳腺肿瘤特征和其他临床预测因素 生存。潜在亚组效应，病例按p53和 乳腺癌HER-2/neu表达与环境因素的关系 在可能的情况下，将探索癌症存活率。